Below are the most recent publications written about "Maximum Tolerated Dose" by people in Profiles.
-
Liu Y, Bollino DR, Bah OM, Strovel ET, Le TV, Zarrabi J, Philip S, Lapidus RG, Baer MR, Niyongere S, Duong VH, Dougherty CC, Beumer JH, Caprinolo KD, Kamangar F, Emadi A. A phase 1 study of the amino acid modulator pegcrisantaspase and venetoclax for relapsed or refractory acute myeloid leukemia. Blood. 2025 01 30; 145(5):486-496.
-
Thomas JS, El-Khoueiry AB, Maurer BJ, Groshen S, Pinski JK, Cobos E, Gandara DR, Lenz HJ, Kang MH, Reynolds CP, Newman EM. A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors. Cancer Chemother Pharmacol. 2021 04; 87(4):525-532.
-
Akingbola TS, Tayo BO, Ezekekwu CA, Sonubi O, Zhang X, Saraf SL, Molokie R, Hsu LL, Han J, Cooper RS, Gordeuk VR. "Maximum tolerated dose" vs "fixed low-dose" hydroxyurea for treatment of adults with sickle cell anemia. Am J Hematol. 2019 04; 94(4):E112-E115.
-
Italiano A, Soria JC, Toulmonde M, Michot JM, Lucchesi C, Varga A, Coindre JM, Blakemore SJ, Clawson A, Suttle B, McDonald AA, Woodruff M, Ribich S, Hedrick E, Keilhack H, Thomson B, Owa T, Copeland RA, Ho PTC, Ribrag V. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol. 2018 05; 19(5):649-659.
-
Koopmeiners JS, Wey A. The Randomized CRM: An Approach to Overcoming the Long-Memory Property of the CRM. J Biopharm Stat. 2017; 27(6):1028-1042.
-
Han J, Bhat S, Gowhari M, Gordeuk VR, Saraf SL. Impact of a Clinical Pharmacy Service on the Management of Patients in a Sickle Cell Disease Outpatient Center. Pharmacotherapy. 2016 11; 36(11):1166-1172.
-
Fitzhugh CD, Hsieh MM, Allen D, Coles WA, Seamon C, Ring M, Zhao X, Minniti CP, Rodgers GP, Schechter AN, Tisdale JF, Taylor JG. Hydroxyurea-Increased Fetal Hemoglobin Is Associated with Less Organ Damage and Longer Survival in Adults with Sickle Cell Anemia. PLoS One. 2015; 10(11):e0141706.
-
Horsley L, Cummings J, Middleton M, Ward T, Backen A, Clamp A, Dawson M, Farmer H, Fisher N, Halbert G, Halford S, Harris A, Hasan J, Hogg P, Kumaran G, Little R, Parker GJ, Potter P, Saunders M, Roberts C, Shaw D, Smith N, Smythe J, Taylor A, Turner H, Watson Y, Dive C, Jayson GC. A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours. Cancer Chemother Pharmacol. 2013 Dec; 72(6):1343-52.
-
Emmenegger U, Francia G, Chow A, Shaked Y, Kouri A, Man S, Kerbel RS. Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. Neoplasia. 2011 Jan; 13(1):40-8.
-
Hsia SH. Insulin glargine compared to NPH among insulin-na?ve, U.S. inner city, ethnic minority type 2 diabetic patients. Diabetes Res Clin Pract. 2011 Mar; 91(3):293-9.